Search results for " Drug"

showing 10 items of 3138 documents

Preradiation chemotherapy of children and young adults with malignant brain tumors: Results of the german pilot trial HIT'88/'89

1998

Background Preradiation chemotherapy could be beneficial in malignant brain tumors, because the blood-brain tumor-barrier is disrupted after surgery, bone marrow recovery--essential for intense chemotherapy--is still intact, and CNS toxicity and ototoxicity of active drugs are lower before irradiation of a child's brain. Patients and methods A neoadjuvant phase 2 and a single arm pilot trial were initiated to investigate the efficacy and toxicity of an intense multidrug regimen before radiotherapy in 147 patients aged between 3 and 29; 9 years with medulloblastoma (94), malignant glioma (22), ependymoma (21), and stPNET (10). They were treated with one or two cycles consisting of procarbazi…

AdultMaleOncologyEpendymomamedicine.medical_specialtyAdolescentmedicine.medical_treatmentPilot ProjectsProcarbazineInternal medicineGliomaAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildSurvival rateMedulloblastomaChemotherapyIfosfamideDose-Response Relationship DrugBrain Neoplasmsbusiness.industrymedicine.diseaseCombined Modality TherapyNeoadjuvant TherapySurgerySurvival RateRegimenChild PreschoolPediatrics Perinatology and Child HealthFemalebusinessFollow-Up Studiesmedicine.drug
researchProduct

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials

2005

Summary Background Chemotherapy is the standard treatment for advanced non-small-cell lung cancer, and myelosuppression is a common side-effect. We aimed to assess whether haematological toxic effects could be a biological measure of drug activity and a marker of efficacy. Methods We analysed data for 1265 patients who received chemotherapy (vinorelbine, gemcitabine, gemcitabine and vinorelbine, cisplatin and vinorelbine, or cisplatin and gemcitabine) within three randomised trials. Primary landmark analyses were restricted to 436 patients who received all six planned chemotherapy cycles and who were alive 180 days after randomisation. Neutropenia was categorised on the basis of worst WHO g…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentAntineoplastic AgentsNeutropenia.VinorelbineSeverity of Illness IndexCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansLung cancerSurvival rateAgedProportional Hazards ModelsRandomized Controlled Trials as TopicAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryStandard treatmentHazard ratioMiddle Agedrandomized clinical trialmedicine.diseaseGemcitabineSurgerySurvival Ratelandmark analysisnon-small-cell lung cancerItalyOncologychemotherapy-induced neutropeniaFemaleDrug MonitoringbusinessBiomarkersmedicine.drug
researchProduct

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Trans…

2019

The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV) DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7.4. Overall, 122 of 167 patients (73%) were all…

AdultMaleOncologymedicine.medical_specialtyPremedicationmedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationAntiviral AgentsAllogeneic hematopoietic stem cells transplantationMechanistic target of rapamycin inhibitorQuantitative PCR03 medical and health sciences0302 clinical medicineTime-to-event analysisInternal medicineHumansTransplantation HomologousMedicineCumulative incidenceCytomegalovirus diseaseSurvival analysisRetrospective StudiesSirolimusTransplantationDose-Response Relationship Drugbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationPK/PDvirus diseasesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseCytomegalovirus infectionsurgical procedures operativeCytomegalovirus DNAemia030220 oncology & carcinogenesisSirolimusCytomegalovirus InfectionsPreemptive antiviral therapySirolimus exposureFemalebusinessSerostatusImmunosuppressive Agents030215 immunologymedicine.drug
researchProduct

Low morphine doses in opioid-naive cancer patients with pain

2006

Cancer pain can be managed in most patients through the use of the analgesic ladder proposed by the World Health Organization. Recent studies have proposed to skip the second "rung" of the ladder by using a so-called "strong" opioid for moderate pain. However, usual doses of strong opioids commonly prescribed for the third rung of the analgesic ladder may pose several problems in terms of tolerability in opioid-naive patients. The aim of this multicenter study was to evaluate the efficacy and tolerability of very low doses of morphine in advanced cancer patients no longer responsive to nonopioid analgesics. A sample of 110 consecutive opioid-naive patients with moderate-to-severe pain were …

AdultMalePainWHO method cancer pain opioids morphineOpioidDose-Response RelationshipQuality of lifeNeoplasmsWHO methodMedicineHumansCancer painOpioid peptideGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsDose-Response Relationship DrugCancer pain; Morphine; Opioids; WHO method; Adult; Aged; Analgesics Opioid; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Morphine; Neoplasms; Pain; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Morphinebusiness.industryCancerMiddle Agedmedicine.diseaseAnalgesics OpioidClinical trialOpioidsTreatment OutcomeAnesthesiology and Pain MedicineTolerabilityOpioidNeurologyAnesthesiaMorphineFemaleNeurology (clinical)DrugbusinessCancer painmedicine.drug
researchProduct

Effects of botulinum toxin type A on vibration induced facilitation of motor evoked potentials in spasmodic torticollis.

2004

It has not been clarified if botulinum toxin (BTX) injection leads to muscle spindle dysfunction in man. This study aimed to test the hypothesis that BTX application reduces the facilitation of a magnetic evoked response (MEP).We used the vibration induced facilitation of an MEP of the sternocleidomastoid muscle (SCM) as a surrogate marker for muscle spindle function in 20 healthy subjects and 10 patients with idiopathic rotational torticollis in whom BTX was injected unilaterally.The increase in the amplitude and area of the MEPs in the clinically not affected and untreated SCM of the patients did not differ significantly from the controls. At baseline, the vibration induced increase in th…

AdultMalePapermedicine.medical_specialtyMuscle spindleSpasmodic Torticolliscomplex mixturesInjections IntramuscularVibrationNeck MusclesMedicineHumansBotulinum Toxins Type ATorticollisAgedDenervationMuscle DenervationDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseEvoked Potentials MotorBotulinum toxinMuscle DenervationSurgeryNerve RegenerationPsychiatry and Mental healthmedicine.anatomical_structureNeuromuscular AgentsAnesthesiaSurgeryFemaleNeurology (clinical)businessSternocleidomastoid musclemedicine.drugTorticollisReinnervationJournal of neurology, neurosurgery, and psychiatry
researchProduct

Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study

2009

Summary Purpose To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults. Methods The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1–2 weeks over a period of…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiepileptic drugsZonisamideIrritabilityStatistics NonparametricEpilepsyYoung AdultRefractorymedicineHumansNonparametricYoung adultAdverse effectPreschoolChildNeurologic ExaminationEpilepsybusiness.industryStatisticsElectroencephalographyDrug ToleranceIsoxazolesmedicine.diseaseMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria InfantileEpilepsy; Zonisamide; Pediatric epilepsy; Antiepileptic drugsAnticonvulsantTolerabilityNeurologyItalyZonisamideChild PreschoolAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessPediatric epilepsyAntiepileptic drugs; Epilepsy; Pediatric epilepsy; Zonisamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Tolerance; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; Italy; Magnetic Resonance Imaging; Male; Neurologic Examination; Statistics Nonparametric; Young Adult; Neurology; Neurology (clinical)medicine.drugFollow-Up Studies
researchProduct

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

2004

Purpose: To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults. Methods: We performed a prospective open label add-on study in 99 patients (age 12 months to 32 years, mean 14 years) with partial or generalised, crypto/symtpomatic seizures. Levetiracetam was added to no more than two baseline AEDs and the efficacy was rated according to seizure type and frequency. Results: LEV was initiated at the starting dose of 10 mg/kg/day with 5-day increments up to 50 mg/kg/day, unless it was not tolerated. Concomitant therapy was generally not modified throughout the study. After a mean fol…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentlevetiracetamefficacyIrritabilityStatistics NonparametricEpilepsyDOUBLE-BLINDantiepileptic drugmedicineHumansprospective trialProspective StudiesChildAdverse effectChi-Square DistributionEpilepsybusiness.industryInfantmedicine.diseasePiracetamAnticonvulsantNeurologyTolerabilityEpilepsy in childrenChild PreschoolAnesthesiaEpilepsy syndromesFemaleTRIALNeurology (clinical)Levetiracetammedicine.symptomtolerability PARTIAL SEIZURESbusinessFollow-Up Studiesmedicine.drug
researchProduct

Sequential treatment of ADHD in mother and child (AIMAC study): importance of the treatment phases for intervention success in a randomized trial

2018

Abstract Background The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1) before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of the Step 2 PCT on child symptoms after the Step 1 treatment. Methods The analysis included 143 mothers and children (aged 6–12 years) both diagnosed with ADHD. The study design was a two-stage, two-arm parallel group trial (Step 1 treatment group [TG]: …

AdultMalePediatricsmedicine.medical_specialtyEfficacylcsh:RC435-571610Motherslaw.inventionTreatment and control groups03 medical and health sciences0302 clinical medicinePharmacotherapy610 Medical sciences MedicineRandomized controlled trialChild of Impaired ParentslawIntervention (counseling)lcsh:PsychiatryMedicineHumans0501 psychology and cognitive sciencesddc:610ChildChildrenProblem BehaviorPsychiatric Status Rating ScalesPsychotropic Drugsbusiness.industryParent training05 social sciencesTreatment phasesAdult treatmentSequential treatmentCombined Modality Therapy3. Good healthPsychotherapyPsychiatry and Mental healthTreatment OutcomeAttention Deficit Disorder with HyperactivityParent trainingParental psychopathologyFemalebusiness030217 neurology & neurosurgery050104 developmental & child psychologyResearch Article
researchProduct

Pattern of symptoms and symptomatic treatment in adults and the aged population: a retrospective analysis of advanced cancer patients followed at hom…

2016

Context Data regarding symptom burden and symptomatic drugs in palliative population in different classes of age are lacking. Objective The aim of this retrospective study was to assess the symptom burden, and the profile of symptomatic drugs in the last four weeks of life in adults and older cancer patients followed at home. Methods Charts of 412 patients were retrospectively analyzed by using a backward analysis. Patients were divided into three groups: adults (<65 years, A), old (65-74 years, O1), very old (75-84 years, O2), and the oldest (≥85 years, O3). Results At -4W Karnofsky status was significantly lower for older people (p = 0.03). No significant effect of age on the vector of sy…

AdultMalePediatricsmedicine.medical_specialtyPalliative careNauseaPopulationSymptomatic treatmentPainHome care03 medical and health sciences0302 clinical medicineElderlyAdvanced cancerNeoplasmsRetrospective analysisOld patientsMedicineHumans030212 general & internal medicineAdvanced cancer; Drugs; Elderly; Home care; Old patients; Palliative care; Symptoms; Medicine (all)Karnofsky Performance StatuseducationAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryMedicine (all)Anti-Inflammatory Agents Non-SteroidalAge FactorsCancerDrugsRetrospective cohort studyNauseaGeneral MedicineMiddle Agedmedicine.diseaseAdvanced cancerHome Care ServicesAnalgesics Opioid030220 oncology & carcinogenesisSymptomsPalliative careAntiemeticsFemalemedicine.symptombusinessCurrent medical research and opinion
researchProduct

Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response

1997

In view of the fact that controlled prospective studies on the benefits of dose escalation of the selective serotonin re-uptake inhibitor (SSRI) paroxetine are lacking, we conducted a double-blind, randomized, parallel-group multicentre study designed to compare the possible benefits of dose escalation of paroxetine and maprotiline in patients suffering from major or minor depression according to modified Research Diagnostic Criteria (RDC) with inadequate treatment response. The study sample consisted of 544 out-patients with different degrees of severity of depression. Patients received either 20 mg paroxetine (n = 271) or 100 mg maprotiline (n = 273) for the first 3 weeks in a double-blin…

AdultMalePersonality InventoryResearch Diagnostic CriteriaDrug Administration Schedulelaw.inventionDouble-Blind MethodRandomized controlled triallawmedicineHumansProspective StudiesMaprotilineProspective cohort studyAdverse effectDepressive DisorderDose-Response Relationship DrugMiddle AgedParoxetineClinical trialParoxetinePsychiatry and Mental healthTreatment OutcomeMaprotilineAnesthesiaAntidepressive Agents Second-GenerationFemaleReuptake inhibitorPsychologymedicine.drugActa Psychiatrica Scandinavica
researchProduct